Bifidobacterium Breve

Bifidobacterium Breve (Bifidobacterium breve) is a gram-positive, anaerobic, rod-shaped bacterium that serves as one of the most abundant probiotic species in the human gut, particularly during infancy. First isolated from the feces of breast-fed infants, it plays a foundational role in establishing a healthy microbiome and supporting balanced immune responses. In clinical nutrition, B. breve is recognized for its unique ability to metabolize a wide range of carbohydrates, producing metabolites that support systemic health and vitality beyond the gastrointestinal tract.

Clinical Benefits & Mechanism of Action

B. breve exerts its effects through several distinct physiological pathways, primarily involving the natural fermentation of dietary fibers and the support of a balanced host immune system:

1.  Short-Chain Fatty Acid (SCFA) Production: B. breve produces high levels of acetate and lactate. These SCFAs contribute to maintaining an optimal luminal pH, supporting natural mucosal defenses against unbeneficial microflora, and serving as vital signaling molecules that interact with G protein-coupled receptors (GPR41/GPR43) to support healthy energy metabolism.
2.  Gut-Brain Axis Modulation: It interacts naturally with the central nervous system by supporting the normal production of Brain-Derived Neurotrophic Factor (BDNF) and promoting a healthy, balanced systemic inflammatory profile (specifically supporting baseline levels of TNF-α and IL-6), which is essential for maintaining optimal cognitive performance, memory retention, and a calm, positive mood.
3.  Metabolic Regulation: Specific strains, such as B. breve B-3, have been shown to support the natural expression of Glucagon-Like Peptide-1 (GLP-1), which helps maintain normal insulin sensitivity and promotes efficient fat oxidation via the gut-microbiota-short-chain fatty acid-IL-27 pathway.
4.  Intestinal Barrier Support: It upregulates the natural expression of tight junction proteins (such as occludin and zonula occludens-1), which helps maintain normal intestinal permeability and supports a strong gut wall baseline to manage the healthy retention of lipopolysaccharides (LPS) within the digestive tract.

Scientific Sources & Clinical Trials

• Role of Bifidobacterium breve PRL2020 in reducing symptoms of antibiotic-associated diarrhea in children.
• Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results from a randomised, clinical trial.
• Bifidobacterium Breve BBr60 Improves Obesity Via the Gut Microbiota-Short-Chain Fatty Acid-IL-27/GLP-1 Axis: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial.
• Effects of Bifidobacterium breve A1 on Cognitive Function in Older Adults with Memory Complaints: A Randomised, Double-Blind, Placebo-Controlled Trial.